Replies to post #129088 on Biotech Values

[oc631]

He could, but it would be somewhat illogical to do so insofar as MNTA and NVS will presumably argue their case on the basis of economic damages to the Lovenox partnership as a unit rather than to each company separately.

But the irreparable harm rests solely on MNTA not the unit?